Literature DB >> 10910710

Leishmania sp: comparative study with Toxoplasma gondii and Trypanosoma cruzi in their ability to initialize IL-12 and IFN-gamma synthesis.

M A Oliveira1, H C Santiago, C R Lisboa, I P Ceravollo, G Trinchieri, R T Gazzinelli, L Q Vieira.   

Abstract

We compared in vitro and in vivo induction of IL-12 (p40) and IFN-gamma by mouse cells stimulated with Toxoplasma gondii, Trypanosoma cruzi, and different species of Leishmania. Spleen cells cultured in vitro with T. cruzi or T. gondii, but not with Leishmania, produced IL-12 (p40) and IFN-gamma. Accordingly, IL-12 (p40) was produced by macrophages stimulated in vitro with live T. cruzi or T. gondii or membrane glycoconjugates obtained from trypomastigotes or tachyzoites. No IL-12 production was detected when macrophages were stimulated with live parasites or glycoconjugates from Leishmania, regardless of priming with IFN-gamma. In vivo, only T. cruzi and T. gondii induced the synthesis of IL-12 and IFN-gamma by mouse spleen cells after intraperitoneal injection of parasites. When injected subcutaneously, live Leishmania sp. induced IL-12 (p40) and IFN-gamma production by draining lymph node cells, albeit the levels were slightly lower than those induced by infection with T. gondii or T. cruzi using the same route. Together our results indicate that under different conditions, the intracellular protozoa T. gondii and T. cruzi are more potent stimulators of IL-12 and IFN-gamma synthesis by host immune cells than parasites of the genus Leishmania. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10910710     DOI: 10.1006/expr.2000.4523

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  6 in total

1.  Intraphagosomal peroxynitrite as a macrophage-derived cytotoxin against internalized Trypanosoma cruzi: consequences for oxidative killing and role of microbial peroxiredoxins in infectivity.

Authors:  María Noel Alvarez; Gonzalo Peluffo; Lucía Piacenza; Rafael Radi
Journal:  J Biol Chem       Date:  2010-11-23       Impact factor: 5.157

2.  T-Cell Immunophenotyping and Cytokine Production Analysis in Patients with Chagas Disease 4 Years after Benznidazole Treatment.

Authors:  Mauricio Llaguno; Marcos Vinicius da Silva; Lara Rocha Batista; Djalma Alexandre Alves da Silva; Rodrigo Cunha de Sousa; Luiz Antonio Pertili Rodrigues de Resende; Valdo Jose Dias da Silva; Eliane Lages-Silva; Carlo José Freire Oliveira; Juliana Reis Machado; Denise Bertulucci Rocha Rodrigues; Dalmo Correia; Virmondes Rodrigues
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

3.  Effects of tropism and virulence of Leishmania parasites on cytokine production by infected human monocytes.

Authors:  A Meddeb-Garnaoui; H Zrelli; K Dellagi
Journal:  Clin Exp Immunol       Date:  2008-11-20       Impact factor: 4.330

4.  Involvement of the chemokine RANTES (CCL5) in resistance to experimental infection with Leishmania major.

Authors:  Helton da Costa Santiago; Carolina Ferreira Oliveira; Luciana Santiago; Fernanda Oliveira Ferraz; Daniele da Glória de Souza; Luiz Antônio Rodrigues de-Freitas; Luís Carlos Crocco Afonso; Mauro Martins Teixeira; Ricardo Tostes Gazzinelli; Leda Quercia Vieira
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

5.  Resistant mice lacking interleukin-12 become susceptible to Trypanosoma cruzi infection but fail to mount a T helper type 2 response.

Authors:  Ana Paula Galvão Da Silva; Jacqueline F Jacysyn; Ises De Almeida Abrahamsohn
Journal:  Immunology       Date:  2003-02       Impact factor: 7.397

6.  A Leishmania murine model to evaluate the immunomodulatory properties of Pythium insidiosum proteins.

Authors:  Tatiana Maria Inêz-Ferreira; Leonel Mendoza; Raquel Vilela; Hélida Monteiro de Andrade; João Paulo Haddad; Fernanda Freire Campos Nunes; Isabela Moreira Gondim; Tânia Mara Pinto Dabés Guimarães; Vicente de Paulo Coelho Peixoto de Toledo
Journal:  Heliyon       Date:  2017-03-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.